Compare Stocks → Trending Stocks Sent To You In Real Time (From Huge Alerts) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADRONASDAQ:ATXINASDAQ:CYADNASDAQ:SVRANASDAQ:VCNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsATXIAvenue Therapeutics$0.15$0.15$0.11▼$1.36$6.68M-0.252.03 million shs491,951 shsCYADCelyad Oncology$0.60$0.67$0.46▼$3.07N/AN/AN/A3,009 shsSVRASavara$4.85-1.2%$4.93$1.63▼$5.70$678.31M0.77787,703 shs356,279 shsVCNXVaccinex$7.50-0.7%$8.65$7.16▼$100.80$6.74M0.7610,213 shs21,590 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%ATXIAvenue Therapeutics+1.06%-3.66%+3.81%-6.32%-85.60%CYADCelyad Oncology0.00%0.00%0.00%0.00%-31.82%SVRASavara-1.22%-0.82%-7.09%+0.62%+137.75%VCNXVaccinex-1.83%-9.63%-10.71%-18.89%-90.84%The AI Defense Stock Set to Soar (Ad)To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.Here's how you can invest >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADROAduro BiotechN/AN/AN/AN/AN/AN/AN/AN/AATXIAvenue Therapeutics3.5788 of 5 stars3.53.00.04.61.80.00.0CYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara1.9612 of 5 stars3.51.00.00.02.62.50.6VCNXVaccinexN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADROAduro BiotechN/AN/AN/AN/AATXIAvenue Therapeutics3.00Buy$32.0020,869.86% UpsideCYADCelyad OncologyN/AN/AN/AN/ASVRASavara3.00Buy$8.2069.07% UpsideVCNXVaccinexN/AN/AN/AN/ACurrent Analyst RatingsLatest SVRA, ATXI, CYAD, ADRO, and VCNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADROAduro Biotech$17.26M0.00N/AN/A$4.07 per share0.00ATXIAvenue TherapeuticsN/AN/AN/AN/A$0.03 per shareN/ACYADCelyad OncologyN/AN/AN/AN/A$0.20 per shareN/ASVRASavaraN/AN/AN/AN/A$1.04 per shareN/AVCNXVaccinex$280K23.84N/AN/A$21.86 per share0.34Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADROAduro Biotech-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/AATXIAvenue Therapeutics-$10.38M-$1.27N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)CYADCelyad Oncology-$43.13MN/A0.00∞N/AN/AN/AN/A3/28/2024 (Estimated)SVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)VCNXVaccinex-$19.82M-$84.56N/A∞N/AN/A-2,667.31%-475.55%4/1/2024 (Estimated)Latest SVRA, ATXI, CYAD, ADRO, and VCNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADROAduro BiotechN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/ACYADCelyad OncologyN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADROAduro BiotechN/A8.918.91ATXIAvenue TherapeuticsN/A1.551.55CYADCelyad Oncology0.341.26N/ASVRASavara0.1915.6615.66VCNXVaccinexN/A0.350.35OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADROAduro Biotech49.93%ATXIAvenue Therapeutics17.34%CYADCelyad OncologyN/ASVRASavara87.93%VCNXVaccinex50.11%Insider OwnershipCompanyInsider OwnershipADROAduro Biotech5.90%ATXIAvenue Therapeutics1.80%CYADCelyad Oncology0.94%SVRASavara4.58%VCNXVaccinex51.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADROAduro Biotech15216.21 millionN/AOptionableATXIAvenue Therapeutics344.26 million43.46 millionNot OptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableSVRASavaraN/A138.15 million131.82 millionOptionableVCNXVaccinex38890,000434,000OptionableSVRA, ATXI, CYAD, ADRO, and VCNX HeadlinesSourceHeadlineShort Interest in Vaccinex, Inc. (NASDAQ:VCNX) Declines By 40.5%americanbankingnews.com - March 28 at 1:54 AMVaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - March 27 at 8:30 AMVaccinex CFO Scott Royer to retire, Jill Sanchez steps ininvesting.com - March 6 at 7:15 PMVaccinex Inc VCNXmorningstar.com - March 2 at 3:46 PMVaccinex, Inc.: Vaccinex Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technologyfinanznachrichten.de - February 21 at 9:42 AMVaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery Platformmarkets.businessinsider.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyfinance.yahoo.com - February 21 at 9:42 AMVaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technologyglobenewswire.com - February 21 at 8:00 AMVaccinex Announces 1-For-14 Reverse Stock Splitmarkets.businessinsider.com - February 15 at 4:28 PMWhy Vaccinex (VCNX) Stock Is Trading Lowermsn.com - February 15 at 4:28 PMVaccinex, Inc. Announces Reverse Stock Splitglobenewswire.com - February 15 at 8:00 AMSteven Cohen's Point72 Asset Management Acquires New Stake in Vaccinex Incfinance.yahoo.com - February 12 at 2:49 PMVaccinex Inc Secures $3.7M in Private Placement Dealmsn.com - February 8 at 10:26 AMWhy Vaccinex (VCNX) Stock Is Popping Offmsn.com - February 7 at 2:45 PMVaccinex Announces Pricing of $3.7 Million PIPE Financingmarkets.businessinsider.com - February 7 at 9:45 AMA phase 1b/2 trial of pepinemab and avelumab as second line therapy for patients with metastatic pancreatic adenocarcinoma.ascopubs.org - January 30 at 7:55 PMNasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rulefinance.yahoo.com - December 4 at 8:50 AMVaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 13 at 9:59 AMVaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meetingfinance.yahoo.com - October 31 at 11:18 AMVaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseasesfinance.yahoo.com - October 26 at 9:40 AMUnderstanding the Risks of Investing in Vaccinex Inc (VCNX)knoxdaily.com - October 17 at 9:03 PMVaccinex Inc [NASDAQ: VCNX] Sees Decrease in Stock Valueknoxdaily.com - October 6 at 7:10 PMWhy Is Vaccinex (VCNX) Stock Up 26% Today?markets.businessinsider.com - October 6 at 8:58 AMVaccinex, Inc.: Vaccinex Announces Pricing of $9.6 Million Public Offeringfinanznachrichten.de - September 29 at 11:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAduro BiotechNASDAQ:ADROChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Avenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.Celyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.VaccinexNASDAQ:VCNXVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.